Xilio Therapeutics, Inc. (XLO)
Largest Insider Buys in Sector
XLO Stock Price History Chart
XLO Stock Performance
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until …
Insider Activity of Xilio Therapeutics, Inc.
Over the last 12 months, insiders at Xilio Therapeutics, Inc. have bought $368,790 and sold $4,240 worth of Xilio Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Xilio Therapeutics, Inc. have bought $10.66M and sold $4,240 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $1.48M.
The last purchase of 485,250 shares for transaction amount of $368,790 was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑04‑02.
List of Insider Buy and Sell Transactions, Xilio Therapeutics, Inc.
| 2024-04-02 | 10 percent owner | 485,250 0.9047% | $0.76 | $368,790 | -35.21% | |||
| 2024-02-08 | Sale | 10 percent owner | 1,000 0.0034% | $0.64 | $640 | +51.40% | ||
| 2024-01-12 | Sale | 10 percent owner | 2,100 0.0088% | $0.83 | $1,743 | +18.01% | ||
| 2024-01-11 | Sale | 10 percent owner | 2,135 0.0083% | $0.87 | $1,857 | +3.52% | ||
| 2021-12-10 | 10 percent owner | 25,000 0.0858% | $9.65 | $241,202 | -70.24% | |||
| 2021-12-09 | 10 percent owner | 4,011 0.0145% | $9.84 | $39,485 | -69.23% | |||
| 2021-12-08 | 10 percent owner | 13,458 0.0484% | $9.62 | $129,474 | -68.51% | |||
| 2021-10-26 | 10 percent owner | 312,500 1.1398% | $16.00 | $5M | -76.08% | |||
| 2021-10-26 | 10 percent owner | 250,000 0.9119% | $16.00 | $4M | -76.08% | |||
| 2021-10-26 | 10 percent owner | 500,000 1.8238% | $16.00 | $8M | -76.08% | |||
| 2021-10-26 | 10 percent owner | 387,500 1.4134% | $16.00 | $6.2M | -76.08% | |||
| 2021-10-26 | 10 percent owner | 312,500 1.1398% | $16.00 | $5M | -76.08% | |||
| 2021-10-26 | 10 percent owner | 187,500 0.6839% | $16.00 | $3M | -76.08% |
Insider Historical Profitability
| GILEAD SCIENCES, INC. | 10 percent owner | 7345473 16.7123% | $1.30 | 1 | 0 | |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 734546 1.6712% | $1.30 | 1 | 3 | <0.0001% |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2805413 6.3828% | $1.30 | 3 | 0 | <0.0001% |
| SV7 Impact Medicine Fund LP | 10 percent owner | 1613632 3.6713% | $1.30 | 1 | 0 | <0.0001% |
| RiverVest Venture Fund IV, L.P. | 10 percent owner | 1441444 3.2796% | $1.30 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bain Capital Life Sciences Investors Llc | $3.03M | 7.6 | 2.81M | 0% | +$0 | 0.24 | |
| Fidelity Investments | $2.06M | 5.17 | 1.91M | 0% | +$0 | <0.0001 | |
| RiverVest | $1.56M | 3.91 | 1.44M | 0% | +$0 | 19.12 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $1.56M | 3.9 | 1.44M | 0% | +$0 | 0.04 | |
| Atlas Venture Life Science Advisors Llc | $1.07M | 2.69 | 992,912 | -64.02% | -$1.91M | 0.1 |